Trulicity 4.5 MG/0.5 ML pen 0.5ML
Ended Awarded
- Contract number
- SPE2DB26FL5N8
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,061
Award facts
- Contract value 100% obligated
- $16,060.77 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $16,060.77 to AmerisourceBergen Drug Corp for the supply of Trulicity 4.5 mg/0.5 mL pens on November 10, 2025, with completion scheduled for November 12, 2025. This firm fixed-price delivery order represents a non-competitive, non-set-aside award executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Trulicity is a diabetes medication commonly used within military and federal healthcare systems to support disease management across the Department of Defense and veteran populations.
This delivery order falls under AmerisourceBergen's comprehensive global pharmaceutical support vehicle, which enables the company to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. As a major pharmaceutical distributor and a critical federal medical procurement vendor, AmerisourceBergen has demonstrated consistent capability to fulfill federal medical supply requirements through multiple competitive awards with DLA. The company's pharmaceutical prime vendor arrangement reflects DLA's strategic approach to maintaining reliable supply chains for essential medications across multiple therapeutic domains, including diabetes care, neurological treatments, and specialty pharmaceuticals required by the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Quick answers
Who was awarded contract SPE2DB26FL5N8?
SPE2DB26FL5N8 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on November 10, 2025.
How much is contract SPE2DB26FL5N8 worth?
The government has obligated $16,061 on SPE2DB26FL5N8.
Is contract SPE2DB26FL5N8 an order under another contract?
Yes. SPE2DB26FL5N8 is a delivery order under SPE2DB20D3103, an indefinite delivery contract.
Was contract SPE2DB26FL5N8 competed?
The extent of competition for SPE2DB26FL5N8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award